TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38862303

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 0
Study: 38862381

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 96

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 96
Study: 38862718

Group type: EXPERIMENTAL
Intervention: Linerixibat for 12 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 147
Study: 38862742

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib for 1 year
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib for 3 years
Number of subjects: 69
Study: 38862815

Group type: EXPERIMENTAL
Intervention: Self-administered mindfulness interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 38862831

Group type: EXPERIMENTAL
Intervention: Current trial (ongoing randomized trial post-pandemic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior studies (two randomized trials conducted before the pandemic)
Number of subjects: 0
Study: 38862899

Group type: EXPERIMENTAL
Intervention: CO-DEPRESCRIBE training program
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 167
Study: 38862908

Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day orally for 14 days on and 7 days off) and nivolumab (360 mg every 3 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anlotinib and nivolumab
Number of subjects: 21
Study: 38862912

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES), 30-min quadriceps NMES, 3 days per week for 12 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 15
Study: 38863022

Group type: EXPERIMENTAL
Intervention: Comprehensive assessments including NPC1 severity rating scale, videofluoroscopic swallowing studies, and CSF collection.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Risk analysis of aspiration
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dietary modifications recommended
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Swallowing outcomes analysis
Number of subjects: 14
Study: 38863026

Group type: EXPERIMENTAL
Intervention: Hydrogen-oxygen gas mixture inhalation (8 hours per day, 3 L/min, hydrogen concentration of 67%, oxygen concentration of 33%)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Oxygen inhalation (8 hours per day, 3 L/min, oxygen concentration of 33%)
Number of subjects: 206
Study: 38863155

Group type: EXPERIMENTAL
Intervention: Fidanacogene elaparvovec (gene therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous FIX replacement products
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild-type FIX control
Number of subjects: 0
Study: 38863591

Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula with extra virgin olive oil (administered 5 days before surgery)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard isoprotein and isoenergetic formula (control group)
Number of subjects: 119
Study: 38863605

Group type: EXPERIMENTAL
Intervention: Adaptive Horsemanship (AH) lessons for 8 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 9
Study: 38863672

Group type: EXPERIMENTAL
Intervention: Intensive inpatient trauma treatment program with prolonged exposure (PE), eye movement desensitization and reprocessing (EMDR), and therapist rotation (TR)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intensive inpatient trauma treatment program
Number of subjects: 6
Study: 38863717

Group type: EXPERIMENTAL
Intervention: Fostemsavir + optimized background therapy
Number of subjects: 371
Study: 38864156

Group type: EXPERIMENTAL
Intervention: Individualised TKA
Number of subjects: 28

Group type: COMPARATOR
Intervention: OTS TKA
Number of subjects: 28
Study: 38864165

Group type: EXPERIMENTAL
Intervention: Individualised TKA
Number of subjects: 385

Group type: COMPARATOR
Intervention: OTS TKA
Number of subjects: 385
Study: 38864155

Group type: EXPERIMENTAL
Intervention: Continuous infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Number of subjects: 7031

Group type: COMPARATOR
Intervention: Intermittent infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Number of subjects: 7031

Group type: EXPERIMENTAL
Intervention: Continuous infusion of β-lactam antibiotics
Number of subjects: 7031

Group type: COMPARATOR
Intervention: Intermittent infusion of β-lactam antibiotics
Number of subjects: 7031
Study: 38864228

Group type: EXPERIMENTAL
Intervention: Regular VP replacement (every 3 months)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Irregular VP replacement (when complications occur)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (7 patients)
Number of subjects: 52
Study: 38864363

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (steroid)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Azathioprine, mycophenolate mofetil, mizoribine, or cyclophosphamide (alone or in combination with steroid therapy)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Fish oil, vitamin E, and tonsillectomy
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Other immunosuppressive therapies
Number of subjects: 686

Group type: COMPARATOR
Intervention: Steroids, other immunosuppressive therapies, or tonsillectomy (when added to optimal supportive care)
Number of subjects: 686
Study: 38864441

Group type: EXPERIMENTAL
Intervention: Successful MitraClip placement
Number of subjects: 30
Study: 38864472

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 38864524

Group type: EXPERIMENTAL
Intervention: HIL-214 (formerly TAK-214) vaccine
Number of subjects: 24
Study: 38864538

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Thermal Ablation
Number of subjects: 593
Study: 38864600

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg b.i.d. plus 1.2 mg midazolam (MDZ) on Days 11 and 14
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg b.i.d. alone on Days 8-10
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 200 mg b.i.d. alone on Days 5-7
Number of subjects: 15

Group type: COMPARATOR
Intervention: Midazolam (MDZ) 1.2 mg alone on Day 1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg b.i.d. on Days 11 and 14
Number of subjects: 15
Study: 38864802

Group type: EXPERIMENTAL
Intervention: COVID-T cells (75,000 or 150,000 IFN-γ+CD3+ cells/m)
Number of subjects: 13
Study: 38864835

Group type: EXPERIMENTAL
Intervention: Postoperative ctDNA not detected
Number of subjects: 143

Group type: COMPARATOR
Intervention: Postoperative ctDNA detected
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Landmark negative predictive value (NPV)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Longitudinal sensitivity
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Longitudinal specificity
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Median lead time from ctDNA detection to radiological recurrence
Number of subjects: 143
Study: 38864969

Group type: EXPERIMENTAL
Intervention: Intralipid 20% (1.5 ml/kg) administered 3 min before aortic cross unclamping
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ringer's Lactate (control group) administered 3 min before aortic cross unclamping
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ringer's Lactate (control group)
Number of subjects: 26
Study: 38865006

Group type: EXPERIMENTAL
Intervention: Multi-pronged intervention including access to an online equity dashboard and equity huddles with population health coordinators (PHCs).
Number of subjects: 10865
Study: 38865059

Group type: EXPERIMENTAL
Intervention: Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Troriluzole (from phase 3 trial NCT03701399)
Number of subjects: 33
Study: 38865064

Group type: EXPERIMENTAL
Intervention: Zinc-vitamin E group (n = 40) received oral zinc (120 mg) and vitamin E (1200 IU) before surgery, followed by 30 mg of zinc and 200 IU of vitamin E daily until 21 days after surgery.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (n = 38) received placebo.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Zinc-vitamin E group (n = 40)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (n = 38)
Number of subjects: 78
Study: 38865084

Group type: EXPERIMENTAL
Intervention: Maternal immune responses to CMV, including anti-pentamer immunoglobulin G antibody concentration and viral load in saliva.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viral loads in urine and saliva samples from mothers of infants with cCMV.
Number of subjects: 0
Study: 38865129

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri high dose (5×10^9 CFU)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri low dose (5×10^8 CFU)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 38865142

Group type: EXPERIMENTAL
Intervention: Retromuscular Sugarbaker mesh placement
Number of subjects: 150

Group type: COMPARATOR
Intervention: Keyhole synthetic mesh placement
Number of subjects: 150
Study: 38865146

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg) subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 2 weeks for 24 weeks
Number of subjects: 311
Study: 38865147

Group type: EXPERIMENTAL
Intervention: Early in-bed Cycling + Usual physiotherapy (n=178)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual physiotherapy alone (n=182)
Number of subjects: 360
Study: 38865168

Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (2 g per kilogram of ideal body weight per day)
Number of subjects: 3511

Group type: COMPARATOR
Intervention: Placebo (Ringer's solution)
Number of subjects: 3511

Group type: EXPERIMENTAL
Intervention: Intravenous amino acids
Number of subjects: 3511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3511
Study: 38865173

Group type: EXPERIMENTAL
Intervention: mHealth tool (eDOL)
Number of subjects: 1427
Study: 38865181

Group type: EXPERIMENTAL
Intervention: Remotely delivered weight loss programs for cancer survivors
Number of subjects: 340
Study: 38865190

Group type: EXPERIMENTAL
Intervention: Throat swab including specimens from the palatine tonsils
Number of subjects: 2315

Group type: COMPARATOR
Intervention: Throat swab from the posterior oropharyngeal wall only
Number of subjects: 2315
Study: 38865296

Group type: EXPERIMENTAL
Intervention: Informed consent to midwifery practices and interventions
Number of subjects: 2849

Group type: EXPERIMENTAL
Intervention: Clinical practices and interventions (e.g., warm compresses, manual perineal protection, vaginal examinations, perineal massage, levator pressure, intermittent catheterization, fundal pressure, episiotomy)
Number of subjects: 2849
Study: 38865672

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 28
Study: 38865671

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing-based molecular assay using urine samples
Number of subjects: 64
Study: 38865678

Group type: EXPERIMENTAL
Intervention: Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without Atezolizumab)
Number of subjects: 0
Study: 38865703

Group type: EXPERIMENTAL
Intervention: Facilitated telemedicine for HCV management
Number of subjects: 45
Study: 38865704

Group type: EXPERIMENTAL
Intervention: Web-based therapist-guided mindfulness-based cognitive behavioral therapy (CBT-M)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Web-based therapist-guided cognitive behavioral therapy (CBT)
Number of subjects: 28
Study: 38866072

Group type: EXPERIMENTAL
Intervention: Minnelide 1.5 mg as monotherapy (Regimen A)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Minnelide 1.25 mg once daily for 21 days Q4 weeks as monotherapy (MTD)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of Minnelide plus paclitaxel (Regimen B & C)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Minnelide (Regimen A)
Number of subjects: 11
Study: 38866095

Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) before CPB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best available treatment without ANH
Number of subjects: 0
Study: 38866096

Group type: EXPERIMENTAL
Intervention: HARMONY 1: culturally-tailored exercise and nutrition education
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HARMONY 2: mindfulness-based stress reduction, exercise, and nutrition education
Number of subjects: 200
Study: 38866139

Group type: EXPERIMENTAL
Intervention: LOCI
Number of subjects: 60

Group type: COMPARATOR
Intervention: Leadership training webinar
Number of subjects: 60
Study: 38866180

Group type: EXPERIMENTAL
Intervention: Dostarlimab plus carboplatin-paclitaxel
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel
Number of subjects: 494
Study: 38866366

Group type: EXPERIMENTAL
Intervention: Infrared spectroscopy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Electronic circular dichroism
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Raman optical activity
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combined classification model based on all spectroscopic methods
Number of subjects: 37
Study: 38866559

Group type: EXPERIMENTAL
Intervention: PENG block (20 mL of 0.3% ropivacaine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SIFICB (30 mL of 0.3% ropivacaine)
Number of subjects: 80
Study: 38866567

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) in addition to usual care (UC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study: 38866575

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Internet-based individual therapy for insomnia (iCBT-I) + TAU
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group therapy for insomnia (GCBT-I) + TAU
Number of subjects: 120
Study: 38866577

Group type: EXPERIMENTAL
Intervention: Management of hepatic artery complications (HAC) after liver transplantation
Number of subjects: 0
Study: 38866822

Group type: EXPERIMENTAL
Intervention: CAR T cell therapy (as referenced in the BNT-211-01 trial, NCT04503278)
Number of subjects: 6
Study: 38866860

Group type: EXPERIMENTAL
Intervention: One-year structured weight loss intervention
Number of subjects: 246

Group type: COMPARATOR
Intervention: Baseline data
Number of subjects: 246

Group type: COMPARATOR
Intervention: Changes from baseline to follow-up
Number of subjects: 246
Study: 38866963

Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Histological assessment
Number of subjects: 147
Study: 38867006

Group type: EXPERIMENTAL
Intervention: Yttrium-90-anti-CD66 antibody
Number of subjects: 0
Study: 38867018

Group type: EXPERIMENTAL
Intervention: HFNC flow 30 l/min, open mouth
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HFNC flow 30 l/min, closed mouth
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HFNC flow 70 l/min, open mouth
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HFNC flow 70 l/min, closed mouth
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation between pressure difference and respiratory effort
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 30 l/min - closed mouth
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 30 l/min - open mouth
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 70 l/min - closed mouth
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 95% Limits of Agreement for 70 l/min - open mouth
Number of subjects: 25
Study: 38867077

Group type: EXPERIMENTAL
Intervention: PSCA-directed CAR T cells (100 million CAR T cells without lymphodepletion, followed by lymphodepletion)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: PSCA-directed CAR T cells
Number of subjects: 14
Study: 38867164

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy protocols
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotic therapy ≥ 4 days
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Prescribing ≥ 2 antibiotics
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Neurologic compromise at ICU admission
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Suspected catheter-related bacteraemia
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: BI site classified as 'other'
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Sepsis with ≥ 2 organ dysfunctions
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Late-onset ventilator-associated pneumonia
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: ≥ 1 risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Respiratory failure at ICU admission
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Aspiration pneumonia
Number of subjects: 134
Study: 38867192

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 733

Group type: COMPARATOR
Intervention: Small-bone flap craniotomy
Number of subjects: 733
Study: 38867195

Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation Technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bowen's Therapy
Number of subjects: 24
Study: 38867198

Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 707
Study: 38867220

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) - primarily herbal medicine (HM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 52
Study: 38867235

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0
Study: 38867257

Group type: EXPERIMENTAL
Intervention: Tunlametinib 9 mg plus vemurafenib 720 mg, twice daily (BID)
Number of subjects: 72
Study: 38867283

Group type: EXPERIMENTAL
Intervention: Experiential Brief Alcohol Intervention (EBAI)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Facilitation (Control)
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: EBAI
Number of subjects: 810
Study: 38867292

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: MRproADM
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: MRproANP
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: TBI
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: aPWV
Number of subjects: 519
Study: 38867309

Group type: EXPERIMENTAL
Intervention: Intensive Prolonged Exposure (iPE) therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard weekly delivered sessions of Prolonged Exposure (PE) therapy
Number of subjects: 140
Study: 38867317

Group type: EXPERIMENTAL
Intervention: Personalized music therapy (MT) for at least 2 hours per day
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Generalized music therapy (MT) for 12.5 hours per day, subdivided into fifteen 50-min periods
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group without music therapy (MT)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Generalized music therapy (MT)
Number of subjects: 153
Study: 38867349

Group type: EXPERIMENTAL
Intervention: Trametinib (oral MEK1/2 inhibitor), administered for a maximum of 12 cycles.
Number of subjects: 10
Study: 38867580

Group type: EXPERIMENTAL
Intervention: Mid-urethral sling (MUS) surgery
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Preoperative condition
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: 10-20 years follow-up after MUS
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Sexually inactive women
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Persistent pain after MUS
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Pain as a reason for not being sexually active
Number of subjects: 1210
Study: 38867582

Group type: EXPERIMENTAL
Intervention: Azacitidine (5 days treatment prior to chemotherapy)
Number of subjects: 31
Study: 38868457

Group type: EXPERIMENTAL
Intervention: Bispectral Index™ (BIS™) monitoring during sedation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sedation management at the discretion of the ICU clinical team
Number of subjects: 26
Study: 38868491

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 19
Study: 38869019

Group type: COMPARATOR
Intervention: Mirikizumab
Number of subjects: 0
Study: 38869034

Group type: EXPERIMENTAL
Intervention: Short-term dual antiplatelet therapy (DAPT)
Number of subjects: 1920
Study: 38869091

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Oxygen mask
Number of subjects: 1301
Study: 38869518

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients (KTR)
Number of subjects: 721
Study: 38869629

Group type: EXPERIMENTAL
Intervention: Endo-App
Number of subjects: 106
Study: 38869632

Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Targeted temperature management
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (eCPR)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Initial rhythm shockable
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Ongoing CPR on hospital admission
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Layperson resuscitation
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Main presumed causes of OHCA
Number of subjects: 559
Study: 38869647

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy
Number of subjects: 405